Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 271 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Severe Pneumonia Clear all
Completed Phase 1 Interventional

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

NCT04644120
View directory record Official record
Conditions
CoronaVirus Disease-2019 (COVID-19)
Interventions
ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 24, 2026, 3:16 PM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 24, 2026, 3:16 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 24, 2026, 3:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Anti-SARS-CoV-2 Immune Plasma

NCT04344977
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Torrance, California • Miami, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 24, 2026, 3:16 PM EDT
Terminated Phase 3 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

NCT04425629
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab combination therapy
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
10,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 24, 2026, 3:16 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 24, 2026, 3:16 PM EDT
Terminated No phase listed Observational

Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2

NCT04320511
View directory record Official record
Conditions
SARS-COV2, Severe Acute Respiratory Syndrome, COVID-19
Interventions
CT-V
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 24, 2026, 3:16 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition

NCT04573634
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Not listed
Lead sponsor
Jill M Kolesar
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 24, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 24, 2026, 3:16 PM EDT
Recruiting No phase listed Observational

Long-Term Study of COVID-19 Infection and Long COVID

NCT07781501
View directory record Official record
Conditions
SARS CoV-2 Post-Acute Sequelae
Interventions
This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms.
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 3:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665
View directory record Official record
Conditions
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Mesenchymal Stem Cell
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 3:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Saliva as Source of Detection for SARS-CoV-2

NCT04424446
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 24, 2026, 3:16 PM EDT
Withdrawn Early Phase 1 Interventional

S-Nitrosylation Therapy of COVID-19

NCT04528771
View directory record Official record
Conditions
SARS-CoV2 Infection, Covid19
Interventions
SNO, Nitrogen gas
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 24, 2026, 3:16 PM EDT
Terminated Phase 3 Interventional

Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

NCT04412772
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 24, 2026, 3:16 PM EDT
Completed No phase listed Observational Results available

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19

NCT04397939
View directory record Official record
Conditions
COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
4,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 24, 2026, 3:16 PM EDT
Recruiting No phase listed Observational

Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence

NCT04448145
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS-CoV 2
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
7 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 3:16 PM EDT
Completed No phase listed Observational

Predictors of Severe COVID-19 Outcomes

NCT04388813
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
Not listed
Lead sponsor
Verily Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 24, 2026, 3:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388
View directory record Official record
Conditions
SARS-CoV-2
Interventions
REGN14256, imdevimab, casirivimab + imdevimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 24, 2026, 3:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

NCT04447469
View directory record Official record
Conditions
COVID
Interventions
mavrilimumab, Placebo
Drug · Other
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years and older
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 24, 2026, 3:16 PM EDT
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 24, 2026, 3:16 PM EDT
Recruiting Phase 3 Interventional

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

NCT05261139
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 24, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 24, 2026, 3:16 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases

NCT05467917
View directory record Official record
Conditions
COVID-19, Households, SARS CoV 2 Infection
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 3:16 PM EDT